Company news

Pulse Biosciences, Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

November 9, 2023

Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

October 29, 2023

Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

October 23, 2023

Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study

October 1, 2023

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

September 28, 2023

Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting

September 26, 2023

Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase

September 6, 2023

Pulse Biosciences Clarifies Details of Recent S-3 Filing

August 23, 2023

Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results

August 9, 2023

Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023

July 26, 2023

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

May 17, 2023

Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results

May 10, 2023

Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

May 2, 2023

Pulse Biosciences Announces $65 Million Private Placement

April 30, 2023

Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023

April 26, 2023

Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results

March 29, 2023

Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023

March 1, 2023

Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium

February 1, 2023

Pulse Biosciences Reports Third Quarter 2022 Financial Results

November 9, 2022

Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022

October 26, 2022

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

October 5, 2022

Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

September 25, 2022

Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation

September 19, 2022

Pulse Biosciences Reports Second Quarter 2022 Financial Results

August 9, 2022

Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System

August 3, 2022

Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022

July 26, 2022

Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering

June 8, 2022

Pulse Biosciences, Inc. Announces Changes to its Rights Offering

May 18, 2022

Pulse Biosciences Reports First Quarter 2022 Financial Results

May 10, 2022

Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022

April 27, 2022

Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference

April 25, 2022

Pulse Biosciences, Inc. Announces Rights Offering

April 13, 2022

Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results

March 30, 2022

Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022

March 20, 2022

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

February 14, 2022

Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission

February 7, 2022

Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 31, 2022

Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results

January 10, 2022

Pulse Biosciences to Participate in the Stephens Annual Investment Conference

November 17, 2021

Pulse Biosciences Reports Third Quarter 2021 Financial Results

November 14, 2021

Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference

November 3, 2021

Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021

November 1, 2021

Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors

October 4, 2021

Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference

September 1, 2021

Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer

August 18, 2021

Pulse Biosciences Reports Second Quarter 2021 Financial Results

August 8, 2021

Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021

July 25, 2021

Pulse Biosciences Announces $50 Million Private Placement

June 30, 2021

Pulse Biosciences Announces First CellFX® Procedure Performed in Canada

June 29, 2021

Pulse Biosciences Announces Health Canada Approval for CellFX® System

June 8, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.